Aug. 18 at 4:55 AM
I'm going to try a cheerful post regarding
$HRTX and what might be a near-term s/p increase based partly on having the ER done, Aug. 8th's "Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile", Aug. 15th's adoption of a "Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value", a possible semi-near term mean reversion which refers to the tendency of a stock's price to move back towards its historical average (mean) over time, after deviating from it, and the healthcare sector raise that's shown in the attached image where "Healthcare" is on the very bottom "HALF YEAR PERFORMANCE", "1 YEAR PERFORMANCE", AND "YEAR TO DATE PERFORMANCE" ... which has now moved to the very top in the time period "1 DAY PERFORMANCE" AND "1 WEEK PERFORMANCE" with all the other timeframes showing a progressive rise upward.
HRTX has a very high level of institutional holders. Many of them may not hold Heron based on any heavy due diligence. It's just a part of their many, many holdings. To me, this implies that Heron could be part of an index and will simply rises along with everything else in the healthcare sector. Maybe ...
Unfortunately, HRTX is not among the top holdings of the SPDR S&P Biotech ETF (XBI) or the iShares Biotechnology ETF (IBB).
- XBI: While XBI tracks the S&P Biotechnology Select Industry Index and includes many biotechnology companies, HRTX is not listed in the top holdings according to sources as of August 15, 2025.
- IBB: Similarly, IBB tracks the Nasdaq Biotechnology Index, but Heron Therapeutics is not currently a major holding, according to recent information.
But, I think there's still hope 🙂👍
